Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GCK | P35557 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13974868 | 0.97 | RORC (0.54) | ALDH1A1GCKLMNARORCKDM4E | |
| SCHEMBL2472684 | 0.89 | MAPT (0.59) | ALDH1A1GCKLMNAKDM4EKMT2A | |
| SCHEMBL18588569 | 0.87 | HSD11B1 (0.56) | ALDH1A1LMNARORCKDM4EHSD11B1 | |
| SCHEMBL13974411 | 0.86 | RORC (0.65) | ALDH1A1LMNARORCKDM4EMAPT | |
| SCHEMBL2472070 | 0.85 | GCK (0.69) | ALDH1A1GCKLMNARORCKDM4E | |
| SCHEMBL13974921 | 0.84 | RORC (0.60) | ALDH1A1GCKRORCKDM4E | |
| SCHEMBL2471947 | 0.83 | POLB (0.61) | ALDH1A1LMNARORCKDM4EKMT2A | |
| SCHEMBL17918 | 0.83 | GCK (0.73) | ALDH1A1GCKKMT2AMEN1MAPT | |
| SCHEMBL13974376 | 0.83 | L3MBTL1 (0.53) | ALDH1A1LMNARORCMAPT | |
| SCHEMBL13974869 | 0.83 | RORC (0.57) | ALDH1A1GCKRORCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357679-B2 | Hexafluoroisopropanol derivatives | MSD OSS B.V. (NL) | 2013-01-22 | — | — | US | disclosed |
| EP-2297118-B1 | N- (1, 1, 1, 3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) BENZYL-N' -ARYLCARBONYLPIPERAZ INE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-10-05 | — | — | EP | disclosed |
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029621-A1 | HEXAFLUOROISOPROPANOL DERIVATIVES | FFAR2, FFAR3, FFAR1 | ALDH1A1 1675/4885GCK 143/4885LMNA 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.